DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma.
DNA methylation
immunotherapy
lung adenocarcinoma (LUAD)
mutation burden
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
07
2021
accepted:
16
08
2021
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
24
9
2021
Statut:
epublish
Résumé
Epigenetic changes of lung adenocarcinoma (LUAD) have been reported to be a relevant factor in tumorigenesis and cancer progression. However, the molecular mechanisms responsible for DNA methylation patterns in the tumor immune-infiltrating microenvironment and in cancer immunotherapy remain unclear. We conducted a global analysis of the DNA methylation modification pattern (DMP) and immune cell-infiltrating characteristics of LUAD patients based on 21 DNA methylation regulators. A DNA methylation score (DMS) system was constructed to quantify the DMP model in each patient and estimate their potential benefit from immunotherapy. Two DNA methylation modification patterns able to distinctly characterize the immune microenvironment characterization were identified among 513 LUAD samples. A lower DMS, characterized by increased CTLA-4/PD-1/L1 gene expression, greater methylation modifications, and tumor mutation burden, characterized a noninflamed phenotype with worse survival. A higher DMS, characterized by decreased methylation modification, a greater stromal-relevant response, and immune hyperactivation, characterized an inflamed phenotype with better prognosis. Moreover, a lower DMS indicated an increased mutation load and exhibited a poor immunotherapeutic response in the anti-CTLA-4/PD-1/PD-L1 cohort. Evaluating the DNA methylation modification pattern of LUAD patients could enhance our understanding of the features of tumor microenvironment characterization and may promote more favorable immunotherapy strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Epigenetic changes of lung adenocarcinoma (LUAD) have been reported to be a relevant factor in tumorigenesis and cancer progression. However, the molecular mechanisms responsible for DNA methylation patterns in the tumor immune-infiltrating microenvironment and in cancer immunotherapy remain unclear.
METHODS
METHODS
We conducted a global analysis of the DNA methylation modification pattern (DMP) and immune cell-infiltrating characteristics of LUAD patients based on 21 DNA methylation regulators. A DNA methylation score (DMS) system was constructed to quantify the DMP model in each patient and estimate their potential benefit from immunotherapy.
RESULTS
RESULTS
Two DNA methylation modification patterns able to distinctly characterize the immune microenvironment characterization were identified among 513 LUAD samples. A lower DMS, characterized by increased CTLA-4/PD-1/L1 gene expression, greater methylation modifications, and tumor mutation burden, characterized a noninflamed phenotype with worse survival. A higher DMS, characterized by decreased methylation modification, a greater stromal-relevant response, and immune hyperactivation, characterized an inflamed phenotype with better prognosis. Moreover, a lower DMS indicated an increased mutation load and exhibited a poor immunotherapeutic response in the anti-CTLA-4/PD-1/PD-L1 cohort.
CONCLUSION
CONCLUSIONS
Evaluating the DNA methylation modification pattern of LUAD patients could enhance our understanding of the features of tumor microenvironment characterization and may promote more favorable immunotherapy strategies.
Identifiants
pubmed: 34552879
doi: 10.3389/fonc.2021.734873
pmc: PMC8450540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
734873Informations de copyright
Copyright © 2021 Yuan, Wei, Wang, Cheng, Zeng, Yang, Zhang, Li and Tang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Cancer. 2020 Mar 12;19(1):53
pubmed: 32164750
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32493845
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Mol Cancer. 2017 Jan 30;16(1):10
pubmed: 28137309
Cell Rep. 2016 Jul 12;16(2):457-471
pubmed: 27346347
Semin Oncol. 2015 Aug;42(4):663-71
pubmed: 26320069
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
pubmed: 16478745
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Nucleic Acids Res. 2018 Nov 2;46(19):10034-10051
pubmed: 30085123
Clin Cancer Res. 2016 Apr 15;22(8):1865-74
pubmed: 27084740
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
J Cancer Res Clin Oncol. 2019 Apr;145(4):1027-1035
pubmed: 30810839
Front Oncol. 2020 Jul 30;10:1141
pubmed: 32850324
Cancer Immunol Immunother. 2021 Oct;70(10):2835-2850
pubmed: 33659999
Epigenomics. 2010 Oct;2(5):657-69
pubmed: 21339843
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
J Clin Invest. 2020 Jun 1;130(6):3113-3123
pubmed: 32125282
Mol Diagn Ther. 2018 Aug;22(4):431-442
pubmed: 29777398
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Clin Exp Med. 2018 Feb;18(1):1-14
pubmed: 28752221
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):E4041-E4050
pubmed: 29632196
Cancers (Basel). 2020 Nov 17;12(11):
pubmed: 33212834
ACS Nano. 2018 Oct 23;12(10):9881-9893
pubmed: 30231203
Biomed Pharmacother. 2018 Jan;97:1493-1500
pubmed: 29793312
Neurology. 2019 Sep 10;93(11):e1093-e1103
pubmed: 31405908
Neuropsychopharmacology. 2013 Jan;38(1):23-38
pubmed: 22781841
Aging (Albany NY). 2020 Nov 21;12(24):25275-25293
pubmed: 33234739
Sci Rep. 2015 Jan 26;5:8020
pubmed: 25620445
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Cancer Immunol Res. 2019 May;7(5):737-750
pubmed: 30842092
Genes Dev. 2016 Apr 1;30(7):733-50
pubmed: 27036965
Immunity. 2018 Apr 17;48(4):626-628
pubmed: 29669246
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Front Oncol. 2021 Jan 28;10:593022
pubmed: 33585210
FEBS Lett. 2011 Jul 7;585(13):2078-86
pubmed: 21146531
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Clin Epigenetics. 2020 Aug 6;12(1):119
pubmed: 32762727
J Transl Med. 2010 Jun 11;8:56
pubmed: 20540720
J Transl Med. 2019 Dec 17;17(1):423
pubmed: 31847905
J Thorac Oncol. 2017 Jun;12(6):943-953
pubmed: 28341226
Cell. 2020 Jul 9;182(1):200-225.e35
pubmed: 32649874
Clin Cancer Res. 2019 Aug 15;25(16):5002-5014
pubmed: 30837276